Details

Autor(en) / Beteiligte

• Schuppan, Detlef
• Mäki, Markku
• Lundin, Knut E.A
• Isola, Jorma
• Friesing-Sosnik, Tina
• Taavela, Juha
• Popp, Alina
• Koskenpato, Jari
• Langhorst, Jost
• Hovde, Øistein
• Lähdeaho, Marja-Leena
• Fusco, Stefano
• Schumann, Michael
• Török, Helga P
• Kupcinskas, Juozas
• Zopf, Yurdagül
• Lohse, Ansgar W
• Scheinin, Mika
• Kull, Karin
• Biedermann, Luc
• Byrnes, Valerie
• Stallmach, Andreas
• Jahnsen, Jørgen
• Zeitz, Jonas
• Mohrbacher, Ralf
• Greinwald, Roland

Titel

A Randomized Trial of a Transglutaminase 2 Inhibitor for Celiac Disease

Ist Teil von

• The New England journal of medicine, 2021-07, Vol.385 (1), p.35-45

Ort / Verlag

Boston: Massachusetts Medical Society

Erscheinungsjahr

2021

Quelle

Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals

Beschreibungen/Notizen

• In a phase 2 proof-of-concept trial, patients with celiac disease controlled on a gluten-free diet were assigned to one of three dose levels of ZED1227 (a selective transglutaminase 2 inhibitor) or placebo. Patients were challenged with 3 g of gluten daily for 6 weeks. Comparison of duodenal-biopsy samples between baseline and 6 weeks showed that ZED1227 attenuated gluten-induced mucosal damage.